Upslope Capital Management Exited West Pharmaceutical (WST) for Better Opportunities
Upslope Capital Management, an investment management company, released its fourth-quarter 2025 investor letter. A copy of the letter can be downloaded here.
West Pharmaceutical Services Inc (WST)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Bayforest Capital Theodoros Tsagaris | 300 | $82,542 | -84% | 0.06% |
| 2. | Sivik Global Healthcare Krishen Sud | 0 | $0 | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $105.14 | 54 | $5,677.40 | 66,251 | 2019-02-28 | Filing | |
| $110.55 | 57 | $6,301.52 | 66,197 | 2018-07-31 | Filing | |
| $93.94 | 335 | $31,468.79 | 66,475 | 2017-10-17 | Filing | |
| $88.89 | 275 | $24,444.31 | 56,540 | 2018-05-15 | Filing | |
| $84.53 | 332 | $28,063.30 | 51,831 | 2016-12-08 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $310.40 | 225 | $69,840.00 | 1,253 | 2024-10-29 | Filing | |
| $310.40 | 478 | $148,371.20 | 1,478 | 2024-10-29 | Filing | |
| $300.00 | 500 | $150,000.00 | 1,478 | 2024-08-19 | Filing | |
| $300.00 | 529 | $158,700.00 | 1,978 | 2024-08-19 | Filing | |
| $365.92 | 617 | $225,772.64 | 43,565 | 2024-05-10 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 318,613 | $87,663,248 | 1.64% | |
| 2. | 278,229 | $76,551,927 | 5.94% | |
| 3. | 251,006 | $69,061,791 | 0.1% | |
| 4. | 176,116 | $48,456,556 | 0.03% | |
| 5. | 159,039 | $43,757,858 | 2.48% |
News See All
KeyBanc Sees Injectable GLP-1s Driving Ongoing Demand for WST
KeyBanc sees limited risk to oral weight loss drugs through 2030, even with the potential approval of an oral version of Wegovy.
14 Best Dividend Growth Stocks to Buy and Hold in 2026
Dividends play a real role in equity returns. Over long stretches of time, they add up.
West Pharmaceutical Services (WST) Rebounded in Q3
Brown Advisory, an investment management company, released its “Brown Advisory Large-Cap Growth Strategy” third-quarter 2025 investor letter. A copy of the letter can be downloaded here.
9 Stocks in Bill Gates' Portfolio That Analysts are Watching
The Bill & Melinda Gates Foundation Trust, based in Seattle formed by the merging of the Gates Learning Foundation and the William H.
TD Cowen Initiates Coverage on West Pharmaceutical (WST) with Buy Rating and $350 Target
On October 29, TD Cowen analyst Brendan Smith initiated coverage of West Pharmaceutical Services, Inc. (NYSE:WST) with a Buy rating and a price target of $350, as reported by The Fly.
13 Best Consistent Dividend Stocks to Buy Now
Dividend stocks have lagged the broader market this year, even though analysts continue to favor them.
West Pharmaceutical Services, Inc. (NYSE:WST) Q3 2025 Earnings Call Transcript
West Pharmaceutical Services, Inc. (NYSE:WST) Q3 2025 Earnings Call Transcript October 23, 2025West Pharmaceutical Services, Inc. beats earnings expectations.
What Makes West Pharmaceutical Services (WST) a Prospective Investment?
Upslope Capital Management, an investment management company, released its third-quarter investor letter. A copy of the letter can be downloaded here.
Improved Investor Confidence Boosted West Pharmaceutical Services (WST)
Conestoga Capital Advisors, an asset management company, released its third-quarter 2025 investor letter. A copy of the letter can be downloaded here.